Power Law company profile

Zogenix

Biotech & Life Sciences · Emeryville, United States · Founded 2006 · IPO 2010 Thoroughbred

Developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases

Valuation

$1.51B

Market cap · 2026

Revenue

$298M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

7 investors on Zogenix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Domain Associates

Life Science Angels

Scale Venture Partners

Clarus Ventures

Series B+ 3 investors entered at this stage

Abingworth

Oxford Finance

Chicago Growth Partners

Global footprint

Where Zogenix has talent and traffic

Workforce by country

5 countries with
team presence

🇺🇸 United States79%

🇬🇧 United Kingdom10.5%

🇫🇷 France5.3%

🇯🇵 Japan2.6%

🇮🇹 Italy2.6%

5 countries shown

Market sentiment

What the market is saying about Zogenix

An AI-synthesized read of the highest-engagement posts about Zogenix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zogenix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles